What is Dermala?
Dermala offers a unique, personalized approach to acne treatment by leveraging the human microbiome and advanced data analytics to enhance skin health. Their comprehensive product line includes supplements, cleansers, moisturizers, and treatment pads, all designed to combat acne effectively from both internal and external perspectives. By emphasizing the importance of balancing the body's ecosystem, Dermala provides customized treatment kits tailored to individual skin assessments, addressing the root causes of acne for individuals seeking effective and science-backed solutions.
How much funding has Dermala raised?
Dermala has raised a total of $6.7M across 1 funding round:
Series A
$6.7M
Series A (2020): $6.7M with participation from Cove Fund II, JJDC, True Wealth Ventures, and Seventure Partners
Key Investors in Dermala
Cove Fund II
Cove Fund II is an investment vehicle focused on transforming home ownership through innovative financial programs. While their primary domain is mortgage alternatives, their participation in Dermala's funding suggests an interest in companies that offer unique solutions to consumer needs, potentially extending to health and wellness.
JJDC
JJDC, or Jnana Jyothi Degree College, is an educational institution. Its involvement in Dermala's funding round is unusual and may represent a strategic partnership or a unique investment arm focused on emerging technologies and health sciences, diverging from its core academic mission.
True Wealth Ventures
True Wealth Ventures is a venture capital fund that specifically invests in women-led companies developing consumer health and sustainable products. Their investment in Dermala aligns with their strategy of backing innovative, women-led businesses that aim to solve next-generation challenges in health and sustainability.
What's next for Dermala?
With the recent major strategic investment, Dermala is poised to accelerate its expansion and further refine its personalized treatment offerings. The company's focus on the intersection of microbiome science and data analytics positions it for significant advancements in the rapidly evolving field of dermatological care. Future developments are likely to include enhanced product innovation, broader market penetration, and deeper integration of their data-driven insights to optimize treatment outcomes for a wider patient base. This strategic financing signals a commitment to scaling operations and solidifying its position as a leader in personalized skin health solutions.
See full Dermala company page
